199 related articles for article (PubMed ID: 35913960)
1. Chemical evidence for the tradeoff-in-the-nephron hypothesis to explain secondary hyperparathyroidism.
Phelps KR; Gemoets DE; May PM
PLoS One; 2022; 17(8):e0272380. PubMed ID: 35913960
[TBL] [Abstract][Full Text] [Related]
2. Tradeoff-in-the-Nephron: A Theory to Explain the Primacy of Phosphate in the Pathogenesis of Secondary Hyperparathyroidism.
Phelps KR
Nutrients; 2017 Apr; 9(5):. PubMed ID: 28445401
[TBL] [Abstract][Full Text] [Related]
3. An examination of multiple explanations for secondary hyperparathyroidism
.
Phelps KR; Mason DL
Clin Nephrol; 2020 Aug; 94(2):70-77. PubMed ID: 32567541
[TBL] [Abstract][Full Text] [Related]
4. Use of sevelamer to examine the role of intraluminal phosphate in the pathogenesis of secondary hyperparathyroidism.
Phelps KR; Stote KS; Mason D
Clin Nephrol; 2014 Sep; 82(3):191-201. PubMed ID: 25079864
[TBL] [Abstract][Full Text] [Related]
5. Parathyroid Hormone, Fibroblast Growth Factor 23, and Parameters of Phosphate Reabsorption.
Phelps KR; Mason DL
Am J Nephrol; 2018; 47(5):343-351. PubMed ID: 29779023
[TBL] [Abstract][Full Text] [Related]
6. Tubular calcium reabsorption and other aspects of calcium homeostasis in primary and secondary hyperparathyroidism.
Phelps KR; Stote KS; Mason D
Clin Nephrol; 2014 Aug; 82(2):83-91. PubMed ID: 24985952
[TBL] [Abstract][Full Text] [Related]
7. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
8. Phosphate homeostasis, parathyroid hormone, and fibroblast growth factor 23 in stages 3 and 4 chronic kidney disease.
Phelps KR; Mason DL; Stote KS
Clin Nephrol; 2016 May; 85(5):251-61. PubMed ID: 26951967
[TBL] [Abstract][Full Text] [Related]
9. Hyporesponsiveness or resistance to the action of parathyroid hormone in chronic kidney disease.
Bover J; Arana C; Ureña P; Torres A; Martín-Malo A; Fayos L; Coll V; Lloret MJ; Ochoa J; Almadén Y; Guirado L; Rodríguez M
Nefrologia (Engl Ed); 2021; 41(5):514-528. PubMed ID: 36165134
[TBL] [Abstract][Full Text] [Related]
10. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
11. The mechanism of parathyroid hormone action on calcium reabsorption by the distal tubule.
Bouhtiauy I; Lajeunesse D; Brunette MG
Endocrinology; 1991 Jan; 128(1):251-8. PubMed ID: 1846100
[TBL] [Abstract][Full Text] [Related]
12. Hyperuricemia is associated with secondary hyperparathyroidism in patients with chronic kidney disease.
Costa TEM; Lauar JC; Innecchi MLR; Coelho VA; Moysés RMA; Elias RM
Int Urol Nephrol; 2022 Sep; 54(9):2255-2261. PubMed ID: 35099689
[TBL] [Abstract][Full Text] [Related]
13. Elderly patients with chronic kidney disease have higher risk of hyperparathyroidism.
Elias RM; Moysés RMA
Int Urol Nephrol; 2017 Oct; 49(10):1815-1821. PubMed ID: 28695313
[TBL] [Abstract][Full Text] [Related]
14. Evocalcet Rescues Secondary Hyperparathyroidism-driven Cortical Porosity in CKD Male Rats.
Hasegawa T; Tokunaga S; Yamamoto T; Sakai M; Hongo H; Kawata T; Amizuka N
Endocrinology; 2023 Feb; 164(4):. PubMed ID: 36718587
[TBL] [Abstract][Full Text] [Related]
15. Treatment Based on Cinacalcet Reduces Oxidative Stress in Hemodialysis Patients with Secondary Hyperparathyroidism.
Kuczera P; Adamczak M; Machnik G; Okopien B; Wiecek A
Nephron; 2018; 139(4):286-292. PubMed ID: 29879701
[TBL] [Abstract][Full Text] [Related]
16. One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism.
Bushinsky DA; Chertow GM; Cheng S; Deng H; Kopyt N; Martin KJ; Rastogi A; Ureña-Torres P; Vervloet M; Block GA
Nephrol Dial Transplant; 2020 Oct; 35(10):1769-1778. PubMed ID: 30859218
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism.
Evenepoel P; Meijers B; Viaene L; Bammens B; Claes K; Kuypers D; Vanderschueren D; Vanrenterghem Y
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1268-76. PubMed ID: 20448073
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.
Gutierrez O; Isakova T; Rhee E; Shah A; Holmes J; Collerone G; Jüppner H; Wolf M
J Am Soc Nephrol; 2005 Jul; 16(7):2205-15. PubMed ID: 15917335
[TBL] [Abstract][Full Text] [Related]
19. Diuretics, calciuria and secondary hyperparathyroidism in the Chronic Renal Insufficiency Cohort.
Isakova T; Anderson CA; Leonard MB; Xie D; Gutiérrez OM; Rosen LK; Theurer J; Bellovich K; Steigerwalt SP; Tang I; Anderson AH; Townsend RR; He J; Feldman HI; Wolf M;
Nephrol Dial Transplant; 2011 Apr; 26(4):1258-65. PubMed ID: 21382989
[TBL] [Abstract][Full Text] [Related]
20. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
